Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/ISRCTN22734699
ISRCTN22734699Active, not recruitingUnknown

QuicDNA - Integration of Liquid Biopsy into Lung Cancer Diagnostic

Aneurin Bevan University Health Board0 sites1,260 target enrollmentStarted: June 19, 2023Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Unknown
Status
Active, not recruiting
Enrollment
1,260
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •1. Be willing and able to provide written informed consent for the study
  • •2. Age 16 years or over on day of signing informed consent
  • •3. Have radiologically suspected advanced stage III (excluding radical treatment) and stage IV lung cancer from CT scan as evaluated and reported by clinical team and/or a radiologist
  • •4. Consent to have a genetic analysis performed on ctDNA from their blood sample
  • •5. Have a performance status of 0 or 3 on the ECOG Performance Scale

Exclusion Criteria

  • •1. Is unable or unwilling to comply with study procedures
  • •2. Stage I, II, or III suspected lung cancer that qualifies for radical treatment (surgery, radical radiotherapy or chemoradiotherapy)
  • •3. Have any known concurrent malignancy

Investigators

Similar Trials

Recruiting
Not Applicable
Using ctDNA to Detect Minimal Residual Disease After Lung Cancer ResectionNon Small Cell Lung Cancer
NCT05254782University Health Network, Toronto360
Not yet recruiting
Not Applicable
Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² StudyLung Cancer
NCT06105177Catharina Ziekenhuis Eindhoven800
Active, not recruiting
Not Applicable
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Non Small Cell Lung Cancer
NCT04703153Lucence Health Inc.151
Recruiting
Phase 2
Using ctDNA to Determine Therapies for Lung CancerNon Small Cell Lung CancerComplete Surgical ResectionCirculating Tumor DNA
NCT04966663University Health Network, Toronto66
Active, not recruiting
Not Applicable
Implementation of Liquid Biopsies During Routine Clinical Care in Patients With Advanced Malignancies (LIQPLAT)Advanced Solid Tumor
NCT06367751University Hospital, Basel, Switzerland159